Aditxt Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ADTX Nasdaq 8731 https://aditxt.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aditxt Inc

Is the Options Market Predicting a Spike in Aditx (ADTX) Stock? - Jan 12th, 2023 1:46 pm
Aditxt Forms Adimune, Inc. as a Wholly Owned Subsidiary with a Focus on Immune Modulation Therapies and Appoints Dr. Friedrich Kapp, Former President of the Therapeutic Business Unit at Schering AG, as its Chairman and CEO - Jan 3rd, 2023 2:00 pm
Implied Volatility Surging for Aditx Therapeutics (ADTX) Stock Options - Dec 5th, 2022 1:52 pm
Aditxt’s (Nasdaq: ADTX) Adimune™ Program Has Initiated the Manufacturing Process of Immunotherapeutic Drug Candidate, ADI™-100 in Preparation for Planned Psoriasis First-in-Human Trials - Oct 21st, 2022 1:00 pm
Aditxt, Inc. (Nasdaq: ADTX) Announces Development and Publication of a Mathematical Model for Predicting Longevity and Variations of Immune Response to Immunization to SARS-CoV-2 Infection - Oct 12th, 2022 1:00 pm
FedEx Features AditxtScore™ Immune Monitoring Center and its Service in Richmond, VA, Highlighting the Importance of Quantifying Immune Health - Oct 7th, 2022 1:00 pm
Aditxt, Inc. (NASDAQ: ADTX) Announces That it Has Regained Compliance with Nasdaq Listing Requirements - Sep 29th, 2022 1:00 pm
Aditxt Inc. (Nasdaq: ADTX) Provides Corporate Highlights Post Reverse Stock Split and Closing of $20M Public Offering - Sep 27th, 2022 1:00 pm
Aditxt Announces Closing of $20.0 Million Public Offering - Sep 20th, 2022 8:09 pm
Aditxt Announces Pricing of $20.0 Million Public Offering - Sep 16th, 2022 1:20 pm
Aditxt, Inc. (Nasdaq: ADTX) Announces 1-for-50 Reverse Stock Split Effective Pre-Market Opening on September 14, 2022 - Sep 13th, 2022 8:15 pm
IBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast featuring Amro Albanna, CEO of Aditxt, Inc. - Aug 2nd, 2022 12:17 pm
Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI™-100 Advancing it Closer to First-in-Human Trials - Jul 8th, 2022 12:30 pm
Premier Medical Laboratory Services Now Offering AditxtScore™ Personalized Immune Test for COVID-19 - Jun 14th, 2022 6:00 pm
Aditxt, Inc. Partners with Guthy-Renker Affiliate GRS to Launch Consumer Awareness Campaign for AditxtScore™ to Accelerate Adoption and Revenue Growth - Apr 14th, 2022 1:00 pm
Aditxt Signs Revenue-Sharing Agreement with Cellvera for up to $30M, and Hosts a Live Business Update Webinar on April 14th - Apr 5th, 2022 12:30 pm
Aditxt to Participate in the 2022 Virtual Growth Conference - Mar 23rd, 2022 12:30 pm